Top Markets
Coin of the day
TSH Biopharm Corporation Limited TSH Biopharm Corporation Limited

TSH Biopharm Corporation Limited

8432
Rank in Stocks #24354
TSH Biopharm Corporation Limited, a subsidiary of TTY Biopharm Company Limited,... TSH Biopharm Corporation Limited, a subsidiary of TTY Biopharm Company Limited, specializes in the development and commercialization of pharmaceutical products. Established in 1999 with its headquarters in Taipei, Taiwan, the company's market reach extends across Taiwan and other Asian territories. Its product portfolio encompasses a variety of therapeutic solutions, including treatments for cardiovascular, central nervous system, and gastrointestinal conditions, among others.
Share Price
$1.61
Last synced: 2026-08-21
Market Cap
$61.66M
Change (1 day)
0.80%
Change (1 year)
0.18%
Country
TW
Trade TSH Biopharm Corporation Limited (8432)

Category

P/E ratio for TSH Biopharm Corporation Limited (8432)
P/E ratio as of 2026 TTM: 0
According to TSH Biopharm Corporation Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for TSH Biopharm Corporation Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.